Global Reach, Local Expertise

East Brunswick, NJ, USA

Home   |   Locations   |   United States   |   New Jersey   |   START New Jersey

Community Partner

New Cancer Patients

6000

START New Jersey operates in partnership with Astera Cancer Care, bringing early-phase oncology research directly to patients across the Northeast US. Led by Dr. Bruno Fang, the site combines Astera’s community-based care model with START’s global research excellence to accelerate access to innovative cancer therapies.

The facility includes a fully dedicated infusion area, on-site exam rooms, a state-of-the-art sterile compounding pharmacy, and a pharmacokinetic (PK) laboratory designed for precision and compliance. START New Jersey also offers private monitoring spaces and a dedicated conference room for sponsor collaboration in addition to in-house laboratory services —ensuring a seamless clinical experience from screening to treatment.

Together, these capabilities position START New Jersey as a key hub for early-phase oncology trials, advancing START’s mission of bringing Hope Through Access to patients where they live.

Explore START New Jersey's Clinical Trials

Clinical Trials

Explore START New Jersey's Clinical Trials

If you are interested in participating in a clinical trial at START, we encourage you to reach out to us. Our team will guide you through the process, answer any questions you may have, and help determine if you are eligible for any ongoing trials.

Principal Investigators

Phase I Clinical Trials

  • 2 exam rooms
  • 2 infusion chairs
  • PK lab
  • Pharmacy including hazardous drug storage and hazardous compounding areas

 

  • Crash cart and ACLS certified staff
  • Infusion pumps
  • Syringe pumps
  • ECG machine
  • Electronic vital signs monitoring and Accucheck
  • All equipment is annually inspected and calibrated
  • Patient Scale

 

START uses a calibrated ECG machine with all procedures and time points performed in accordance with the protocol. Centralized readings are available when needed, in collaboration with central vendors.

Investigational Drug Section (IDS)

Drug Shipment

  • START New Jersey
  • ATTN: START – Genevieve Kumapley, PharmD, BCOP 
  • 629 Cranbury Rd., 2nd Floor, East Brunswick, NJ 08816

Pharmacy Equipment

  • Refrigerator
  • 1 pharmaceutical grade -20°C freezer
  • 1 pharmaceutical grade -80°C freezer
  • Secure medication storage with continuous temperature and humidity monitoring
  • All equipment is annually inspected and calibrated

Medication Preparation

  • Detailed storage, handling and preparation instructions are required.
  • Procedure to prepare investigational drug
  • Compatible IV bags and syringes
  • Compatible IV tubing for infusion pumps

Medication Screening

Pharmacists screen and document prestudy concominant medications using protocol eligibility criteria, Lexicomp and Crediblemedgs.org to identify prohibited medications and other potential drug interactions of concern.

Drug Accountability

Master accountability log is maintained for each study. Due to the potential for staff exposure to hazardous materials, the IDS does not maintain any empty or partially empty container left from the preparation of investigational doses, this includes both IV and PO dosage forms.

Pharmacokinetics

PK Shipment Address

629 Cranbury Rd., 2nd Floor, East Brunswick, NJ 08816

Laboratory Equipment

  • Refrigerated / room temperature centrifuges 
  • -20°C freezer with continuous temperature monitoring
  • -80°C freezer with continuous temperature monitoring

Shipping Capabilities

PK department staff are IATA shipping certified. Specimens may be shipped same day, weekly, or monthly.

Biopsy Specimens

PK department staff sare present at the time of biopsy and process specimens according to protocol requirements.

Archival Specimens

  • PK department staff request and process archival specimens
  • Unstained slides are obtained and sent to sponsor or designee

Specialty Labs

PK department staff routinely process and ship to Central lab specimens such as biomarkers, PBMCs, DNA, hair follicle specimens, and other specialty labs.

Regulatory Affairs & Data Management

START’s IRB of Record

Advarra IRB

Requirements for IRB Submission

  • Final Protocol
  • Investigator Brochure (IB)
  • IND number
  • Patient stipend
  • Consent form template, which should contain:
    • Reading at a grade level 8.9 or below
    • Total blood volume (in mL) required per protocol
    • Injury statement language
    • Drug Diary Template

Standard START Templates & Training

  • Site Initiation Visit (SIV) Log
  • Site Signature / Delegation of Authority Log
  • Staff complete Good Clinical Practice (GCP) Training & Protection of Human Research Subjects (PHRS) every 3 years via the NIDA Program

Data Entry Capabilities

  • Every study has a dedicated START Data Coordinator. 
  • START has experience with a wide variety of electronic data capture systems (i.e. Medidata RAVE, InForm, Tempo, DataTrak, etc.). 
  • START ensures clean, accurate, and timely data entry and query resolution.
  • 10 business days for data entry
  • 5 business days for query resolution

On-Site Monitoring Area

  • Monitoring workspace with high-speed internet and computer for accessing the EMR
  • WiFi available for EDC access
  • Basic office supplies, copier, and telephone are available
  • On-site monitoring hours are: Monday-Friday, 8:00 AM – 3:00 PM ET

Remote Monitoring Services

  • START’s remote monitoring service allows the monitor to have access to our EMR and e-ISF (Veeva) systems without having to be onsite.
  • Remote monitoring hours are: Monday-Friday*, 8:00 AM – 3:00 PM ET (*Flexible hours are available, provided that any adjustments are agreed upon between the coordinators and the monitors.)

Scheduling Monitoring Visits

  • The START Data Coordinator is the main point of contact for the scheduling of all on-site and/or remote monitoring visits (i.e. initial, interim, and close-out visits, etc.).
  • Monitor visits must be scheduled at least 30 days in advance.
  • Requests for co-monitors must be reviewed by the study team and approved by the Principal Investigator.

Hybrid Monitoring (Onsite and Remote)

  • Monitors will be required to conduct onsite and remote visits during the following times:
  • First monitoring visit and once per quarter may be conducted ONSITE.
  • All other visits will be conducted REMOTELY.

Contact

Get in Touch

Let’s save lives—together. Fill out the form to connect with us today, whether you’re ready to jump in or just have questions. Every action counts.

Other Locations